• Options for augmentation in treatment-resistant age-related depression

    A substantial proportion geriatric patients taking antidepressants do not respond to therapy. Should they switch completely, just augment, and how?

  • A day at the ER: How many diagnoses can AI correctly make?

    ChatGPT could solve many questions on a medical exam, but using it on real people would quickly prove fatal, says a doctor who has put it to the test.

  • NET: What gastroenterologists should know

    Even gastroenterologists may struggle with this very special and heterogeneous group of neoplasms. But a correct diagnosis is usually within their grasp.

  • Psychedelics in psychiatry: yesterday, today, and tomorrow?

    In psychiatric therapy research, psychedelic-assisted psychotherapy is currently one of the most exciting areas of research. What trends could await us?

  • Psychedelic Augmented Psychotherapy: Science vs. Expectation

    Some patients seek psychedelic-augmented psychotherapy with quite high expectations. How should therapists approach this?

  • Obesity: can a healthy gut microbiome contribute to treatment?

    If the intestinal microbiome is unbalanced, chronic diseases or micro-inflammations often ensue. What role does intestinal flora dysfunction play in grade III obesity?

  • Medical Case: Patient with diarrhoea and lower abdominal pain

    A 20-year-old woman arrives to the emergency room with lower abdominal pain and changes in bowel movements. What is your probable diagnosis?

  • Dr Prateep Beed on psychedelics research, and its expanding contribution to medicine

    In this interview, Dr. Beed's global snapshot of today's psychedelics research covers therapeutics, policies, patient-doctor relations, and medical specialties.

  • Surgery for gastrointestinal tumours: Could AI take over soon?

    Artificial intelligence has also arrived in the operating room. Will it replace surgeons in the future?

  • Icons, gurus, and boundaries: Professional risks in psychedelic therapy settings

    Prof. Dr. Matthew Johnson looks at the challenges posed to psychedelics science professionals by patients' experiences and experimental settings.

  • Evidence-based psychedelic therapy: driven by science, away from bogus spiritual fixes

    Dr Henrik Jungaberle covers the INSIGHT 2023 themes, and the importance of scientific rigour in the expanding field of psychedelic therapy.

  • MDMA: a new hope for young people with PTSD

    Research is evaluating risks and suitability of MDMA assisted therapy for 15-17 year olds with PTSD. Ethically rigorous studies are needed to evaluate safety and efficacy.

  • Psilocybin: new therapeutic perspectives

    The two pilot studies, one on depression in Alzheimer's and one on Lyme disease, assess if psilocybin offers alternatives to ineffective standard treatments.

  • New ESC Guidelines 2023: An overview

    Five new guidelines were presented in the ESC Congress: acute coronary syndromes; heart failure; cardiomyopathies; cardio-vascular disease and diabetes; and endocarditis.

  • Interview: Psychedelic therapy in Italy, a long road ahead

    Where does Italy stand in psychedelic drug research? We discuss this with Dr Matteo Buonarroti, the first Italian doctor to complete the Mind Foundation's Augmented Psychotherapy Training.

  • ESC guidelines for all acute coronary syndromes published

    Cardiovascular events are the number one cause of death. Guidelines for all acute coronary syndromes have been published just in time for the 2023 ESC Congress.

  • The ZePrion experiment: set in space to fight diseases on earth

    The experiment, sent to the ISS, looks into the molecular mechanism behind an innovative pharmaceutical protocol to combat prion diseases.

  • Analysis: First aid in case of drowning

    Drowning deaths are a serious public health problem worldwide. Drowning victims require rapid and skilled intervention.

  • How does neutropenia increase the risk of AML and MDS?

    Severe congenital neutropenia increases the risk of myelodysplastic syndrome and acute myeloid leukaemia. What do we know today about the haematological processes that lead to leukaemogenesis?

  • Transthyretin amyloid cardiomyopathy (ATTR-CM): A promising new antibody

    No drug tackled the cause of ATTR-CM - the deposition of misfolded transthyretin in the heart muscle tissue. Until a phase I study tested a new recombinant antibody.

  • 11 |
  • 12 |
  • 13 |
  • 14 |
  • 15 |
  • 16 |
  • 17 |
  • 18 |
  • 19 |
  • 20 |
  • 21 |